T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant

Cancer Letters

Volumn 344, Issue 1, 2014, Pages 90-100

  Kirkegaard, Tove ^a   Hansen, Susanne K ^a   Larsen, Sarah L ^a   Reiter, Birgit E ^a   Sørensen, Boe S ^b   Lykkesfeldt, Anne E ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Antiestrogen resistance; Breast cancer; C Src; Fulvestrant; HER2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FULVESTRANT; PROTEIN TYROSINE KINASE;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CELL STRAIN MCF 7; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN ANTAGONISTS; HUMANS; IMMUNOPRECIPITATION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 84893698272     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.10.014     Document Type: Article

References (61)

1. Davies C., Godwin J., Gray R., Clarke M., Cutter D., Darby S., McGale P., Pan H.C., Taylor C., Wang Y.C., Dowsett M., Ingle J., Peto R. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378:771-784.
2. Valachis A., Mauri D., Polyzos N.P., Mavroudis D., Georgoulias V., Casazza G. Fulvestrant in the treatment of advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials. Crit. Rev. Oncol. Hematol. 2010, 73:220-227.
3. Howell A. Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocr. Relat. Cancer 2006, 13:689-706.
4. Wakeling A.E., Dukes M., Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991, 51:3867-3873.
5. Osborne C.K., Coronado-Heinsohn E.B., Hilsenbeck S.G., McCue B.L., Wakeling A.E., McClelland R.A., Manning D.L., Nicholson R.I. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J. Natl. Cancer Inst. 1995, 87:746-750.
6. Osborne C.K., Pippen J., Jones S.E., Parker L.M., Ellis M., Come S., Gertler S.Z., May J.T., Burton G., Dimery I., Webster A., Morris C., Elledge R., Buzdar A. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J. Clin. Oncol. 2002, 20:3386-3395.
7. Howell A., Robertson J.F., Quaresma A.J., Aschermannova A., Mauriac L., Kleeberg U.R., Vergote I., Erikstein B., Webster A., Morris C. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J. Clin. Oncol. 2002, 20:3396-3403.
8. Masamura S., Santner S.J., Heitjan D.F., Santen R.J. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J. Clin. Endocrinol. Metab. 1995, 80:2918-2925.
9. Osborne C.K., Shou J., Massarweh S., Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin. Cancer Res. 2005, 11:865s-870s.
10. Mehta R.S., Barlow W.E., Albain K.S., Vandenberg T.A., Dakhil S.R., Tirumali N.R., Lew D.L., Hayes D.F., Gralow J.R., Livingston R.B., Hortobagyi G.N. Combination anastrozole and fulvestrant in metastatic breast cancer. N. Engl. J. Med. 2012, 367:435-444.
11. Bergh J., Jonsson P.E., Lidbrink E.K., Trudeau M., Eiermann W., Brattstrom D., Lindemann J.P., Wiklund F., Henriksson R. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J. Clin. Oncol. 2012, 30:1919-1925.
12. Lykkesfeldt A.E., Sorensen E.K. Effect of estrogen and antiestrogens on cell proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF-7 and a tamoxifen resistant variant subline, AL-1. Acta Oncol. 1992, 31:131-138.
13. Lykkesfeldt A.E., Madsen M.W., Briand P. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res. 1994, 54:1587-1595.
14. Lykkesfeldt A.E., Larsen S.S., Briand P. Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int. J. Cancer 1995, 61:529-534.
15. Sommer A., Hoffmann J., Lichtner R.B., Schneider M.R., Parczyk K. Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines. J. Steroid Biochem. Mol. Biol. 2003, 85:33-47.
16. McClelland R.A., Barrow D., Madden T.A., Dutkowski C.M., Pamment J., Knowlden J.M., Gee J.M., Nicholson R.I. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 2001, 142:2776-2788.
17. Massarweh S., Osborne C.K., Creighton C.J., Qin L., Tsimelzon A., Huang S., Weiss H., Rimawi M., Schiff R. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008, 68:826-833.
18. Nicholson R.I., Hutcheson I.R., Harper M.E., Knowlden J.M., Barrow D., McClelland R.A., Jones H.E., Wakeling A.E., Gee J.M. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr. Relat. Cancer 2001, 8:175-182.
19. Ghayad S.E., Vendrell J.A., Ben L.S., Dumontet C., Bieche I., Cohen P.A. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int. J. Cancer 2010, 126:545-562.
20. Knowlden J.M., Hutcheson I.R., Jones H.E., Madden T., Gee J.M., Harper M.E., Barrow D., Wakeling A.E., Nicholson R.I. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003, 144:1032-1044.
21. Thrane S., Lykkesfeldt A.E., Larsen M.S., Sorensen B.S., Yde C.W. Estrogen receptor alpha is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. Breast Cancer Res. Treat. 2013, 139:71-80.
22. Brunner N., Frandsen T.L., Holst-Hansen C., Bei M., Thompson E.W., Wakeling A.E., Lippman M.E., Clarke R. MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res. 1993, 53:3229-3232.
23. Frogne T., Jepsen J.S., Larsen S.S., Fog C.K., Brockdorff B.L., Lykkesfeldt A.E. Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth. Endocr. Relat. Cancer 2005, 12:599-614.
24. Frogne T., Benjaminsen R.V., Sonne-Hansen K., Sorensen B.S., Nexo E., Laenkholm A.V., Rasmussen L.M., Riese D.J., de Cremoux P., Stenvang J., Lykkesfeldt A.E. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res. Treat. 2009, 114:263-275.
25. Frankel L.B., Lykkesfeldt A.E., Hansen J.B., Stenvang J. Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells. Breast Cancer Res. Treat. 2007, 104:165-179.
26. Sonne-Hansen K., Norrie I.C., Emdal K.B., Benjaminsen R.V., Frogne T., Christiansen I.J., Kirkegaard T., Lykkesfeldt A.E. Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance. Breast Cancer Res. Treat. 2010, 121:601-613.
27. Nabha S.M., Glaros S., Hong M., Lykkesfeldt A.E., Schiff R., Osborne K., Reddy K.B. Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells. Oncogene 2005, 24:3166-3176.
28. Pancholi S., Lykkesfeldt A., Hilmi C., Banerjee S., Leary A., Drury S., Johnston S., Dowsett M., Martin L.A. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and p90RSK. Endocr. Relat. Cancer 2008, 15:985-1002.
29. Zahnow C.A. ErbB receptors and their ligands in the breast. Expert. Rev. Mol. Med. 2006, 8:1-21.
30. Gullick W.J. C-erbB-4/HER4: friend or foeα. J. Pathol. 2003, 200:279-281.
31. Witton C.J., Reeves J.R., Going J.J., Cooke T.G., Bartlett J.M. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J. Pathol. 2003, 200:290-297.
32. Tovey S., Dunne B., Witton C.J., Forsyth A., Cooke T.G., Bartlett J.M. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancerα. Clin. Cancer Res. 2005, 11:4835-4842.
33. Frogne T., Laenkholm A.V., Lyng M.B., Henriksen K.L., Lykkesfeldt A.E. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast Cancer Res. 2009, 11:R11.
34. Rasmussen B.B., Andersson M., Christensen I.J., Moller S. Evaluation of and quality assurance in HER2 analysis in breast carcinomas from patients registered in Danish Breast Cancer Group (DBCG) in the period of 2002-2006. A nationwide study including correlation between HER-2 status and other prognostic variables. Acta Oncol. 2008, 47:784-788.
35. Dowsett M., Procter M., Caskill-Stevens W., de A.E., Dafni U., Rueschoff J., Jordan B., Dolci S., Abramovitz M., Stoss O., Viale G., Gelber R.D., Piccart-Gebhart M., Leyland-Jones B. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J. Clin. Oncol. 2009, 27:2962-2969.
36. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
37. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., Cameron D., Dowsett M., Barrios C.H., Steger G., Huang C.S., Andersson M., Inbar M., Lichinitser M., Lang I., Nitz U., Iwata H., Thomssen C., Lohrisch C., Suter T.M., Ruschoff J., Suto T., Greatorex V., Ward C., Straehle C., McFadden E., Dolci M.S., Gelber R.D. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 2005, 353:1659-1672.
38. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344:783-792.
39. Rasmussen B.B., Regan M.M., Lykkesfeldt A.E., Dell'Orto P., Del C.B., Henriksen K.L., Mastropasqua M.G., Price K.N., Mery E., Lacroix-Triki M., Braye S., Altermatt H.J., Gelber R.D., Castiglione-Gertsch M., Goldhirsch A., Gusterson B.A., Thurlimann B., Coates A.S., Viale G. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol. 2008, 9:23-28.
40. Benz C.C., Scott G.K., Sarup J.C., Johnson R.M., Tripathy D., Coronado E., Shepard H.M., Osborne C.K. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat. 1992, 24:85-95.
41. Johnston S., Pippen J., Pivot X., Lichinitser M., Sadeghi S., Dieras V., Gomez H.L., Romieu G., Manikhas A., Kennedy M.J., Press M.F., Maltzman J., Florance A., O'Rourke L., Oliva C., Stein S., Pegram M. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J. Clin. Oncol. 2009, 27:5538-5546.
42. Yeatman T.J. A renaissance for SRC. Nat. Rev. Cancer 2004, 4:470-480.
43. Irby R.B., Yeatman T.J. Role of Src expression and activation in human cancer. Oncogene 2000, 19:5636-5642.
44. Elsberger B., Fullerton R., Zino S., Jordan F., Mitchell T.J., Brunton V.G., Mallon E.A., Shiels P.G., Edwards J. Breast cancer patients' clinical outcome measures are associated with Src kinase family member expression. Br. J. Cancer 2010, 103:899-909.
45. Hiscox S., Jordan N.J., Smith C., James M., Morgan L., Taylor K.M., Green T.P., Nicholson R.I. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Res. Treat. 2009, 115:57-67.
46. Biscardi J.S., Belsches A.P., Parsons S.J. Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells. Mol. Carcinog. 1998, 21:261-272.
47. Belsches-Jablonski A.P., Biscardi J.S., Peavy D.R., Tice D.A., Romney D.A., Parsons S.J. Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene 2001, 20:1465-1475.
48. Wilson G.R., Cramer A., Welman A., Knox F., Swindell R., Kawakatsu H., Clarke R.B., Dive C., Bundred N.J. Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. Br. J. Cancer 2006, 95:1410-1414.
49. Maa M.C., Leu T.H., McCarley D.J., Schatzman R.C., Parsons S.J. Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. Proc. Natl. Acad. Sci. USA 1995, 92:6981-6985.
50. Muthuswamy S.K., Siegel P.M., Dankort D.L., Webster M.A., Muller W.J. Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Mol. Cell Biol. 1994, 14:735-743.
51. Ishizawar R.C., Miyake T., Parsons S.J. C-Src modulates ErbB2 and ErbB3 heterocomplex formation and function. Oncogene 2007, 26:3503-3510.
52. Memon A.A., Sorensen B.S., Meldgaard P., Fokdal L., Thykjaer T., Nexo E. The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. Br. J. Cancer 2006, 94:1703-1709.
53. Memon A.A., Sorensen B.S., Melgard P., Fokdal L., Thykjaer T., Nexo E. Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients. Br. J. Cancer 2004, 91:2034-2041.
54. Lundholt B.K., Briand P., Lykkesfeldt A.E. Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways. Breast Cancer Res. Treat. 2001, 67:199-214.
55. DeFriend D.J., Howell A., Nicholson R.I., Anderson E., Dowsett M., Mansel R.E., Blamey R.W., Bundred N.J., Robertson J.F., Saunders C., et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res. 1994, 54:408-414.
56. Fan P., McDaniel R.E., Kim H.R., Clagett D., Haddad B., Jordan V.C. Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines. Eur. J. Cancer 2012, 48:3488-3498.
57. Murphy C.S., Pink J.J., Jordan V.C. Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions. Cancer Res. 1990, 50:7285-7292.
58. Pink J.J., Jordan V.C. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res. 1996, 56:2321-2330.
59. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., Stewart S.J., Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20:719-726.
60. Ottenhoff-Kalff A.E., Rijksen G., van Beurden E.A., Hennipman A., Michels A.A., Staal G.E. Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res. 1992, 52:4773-4778.
61. Doble B.W., Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 2003, 116:1175-1186.